La Jolla's flagship product is GCS-100, which is t
Post# of 66
La Jolla's flagship product is GCS-100, which is the company's only compound in clinical development right now.
The compound targets a protein known as Galectin-3, which makes it a viable candidate for quite a few indications. La Jolla is developing it as a treatment for kidney disease, cancer immunotherapy, anti-chemotherapy, and as a supplementary treatment for renal transplantation. It's hard to tell which indication will garner the most interest this early on in clinical development, but I will personally be following its profile as a cancer drug most closely.
Recently, the company announced that the first patient has been dosed in the phase I/II trial for GCS-100 as a kidney disease treatment. This trial, if successful, will start to form an overall safety profile for GCS-100 and might draw some new interest towards the stock as a result (which could also provide some much-needed liquidity on this ticker).
Share Structure
Market Value1 $1,154,584 a/o Jan 29, 2013
Shares Outstanding 13,567,383 a/o Nov 02, 2012
Float Not Available
Authorized Shares 12,008,000,000 a/o Jun 07, 2012
Par Value 0.01
Shareholders
Shareholders of Record 226 a/o Apr 14, 2011
About GCS-100
GCS-100 is a complex polysaccharide that has the ability to bind to and block the effects of galectin-3. Galectin-3 is a soluble protein, over-expression of which has been implicated in a number of human diseases including cancer and chronic organ failure. The unique ability of GCS-100 to bind and sequester galectin-3 makes it an ideal candidate to prevent and treat diseases in which galectin-3 plays an important role.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company dedicated to the development of medical treatments that significantly improve outcomes in patients with life-threatening diseases. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. For more information on the Company please visit http://www.ljpc.com.
(0)
(0)